NCT00851136已完成1 期
A Phase Ib Study of the Safety and Pharmacokinetics of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 9
- 主要终点
- Incidence and nature of dose-limiting toxicities
研究概览
简要总结
This will be a multicenter, open-label study enrolling a total of up to 23 patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed CRC with evidence of locally advanced recurrent or metastatic disease and measurable tumor lesions
- •Life expectancy > 3 months
- •For patients of reproductive potential (males and females), use of reliable means for contraception throughout the trial and for 6 months following their final exposure to study treatment
- •Willingness and capability to be accessible for study follow-up
排除标准
- •Prior 5-FU, capecitabine, and/or oxaliplatin treatment with the exception of: prior oxaliplatin treatment≤ 6 weeks in the advanced or metastatic setting; prior treatment with 5-FU, capecitabine, and/or oxaliplatin in the adjuvant setting if relapse occurred > 6 months from concluding adjuvant therapy
- •Peripheral neuropathy Grade ≥ 2
- •Prior radiotherapy to a measurable metastatic lesion(s) to be used for response assessment, unless the lesion has progressed subsequent to the radiotherapy
- •Radiotherapy to a peripheral lesion within 14 days prior to Cycle 1, Day 1, or radiotherapy to a thoracic, abdominal, or pelvic field within 28 days prior to Cycle 1, Day 1
- •Chemotherapy, hormonal therapy, or immunotherapy within 4 weeks prior to Cycle 1, Day 1
- •Evidence of clinically detectable ascites
- •Other invasive malignancies within 5 years prior to Cycle 1, Day 1
- •History or evidence upon physical examination of active central nervous system (CNS) disease
- •Current or recent participation in another experimental drug study
- •Clinically significant cardiovascular disease, New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia within 1 year prior to Cycle 1, Day 1, or Grade II or greater peripheral vascular disease
- •Active infection requiring parenteral antibiotics
- •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Cycle 1, Day 1, fine needle aspirations within 7 days prior to Cycle 1, Day 1, or anticipation of need for major surgical procedure during the course of the study
- •Known or suspected to be positive for the human immunodeficiency virus (HIV)
- •Known to be positive for hepatitis C or hepatitis B surface antigen
- •Inadequately controlled hypertension
- •Prior history of hypertensive crisis or hypertensive encephalopathy
- •History of arterial thromboembolic event 6 months prior to Cycle 1, Day 1
- •History of abdominal fistula or gastrointestinal perforation within 6 months prior to Cycle 1, Day 1
- •Bleeding diathesis or coagulopathy
- •Pregnancy (positive pregnancy test) or breast feeding
- •Serious, non-healing wound, ulcer, or bone fracture
研究组 & 干预措施
1
Experimental
干预措施: FOLFOX (Drug)
1
Experimental
干预措施: bevacizumab (Drug)
1
Experimental
干预措施: PRO95780 (Drug)
结局指标
主要结局
Incidence and nature of dose-limiting toxicities
时间窗: Length and study
次要结局
- Incidence, nature, and severity of adverse events(Length of study)
- Change in vital signs(Length of study)
- Incidence of anti-PRO95780 antibodies(Length of study)
- Incidence and severity of infusion reactions(Length of study)
- Change in clinical laboratory results(Length of study)
研究者
相似试验
已完成
1 期
A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal CancerMetastatic Colorectal CancerNCT00873756Genentech, Inc.23
已完成
1 期
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic ArthritisJuvenile Idiopathic ArthritisNCT01904292Hoffmann-La Roche52
已完成
1 期
A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's LymphomaNon-Hodgkin's LymphomaNCT00556699Genentech, Inc.22
已完成
1 期
A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic MelanomaMetastatic MelanomaNCT03875079Hoffmann-La Roche83
已完成
1 期
Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid TumorsSolid TumorsNCT01988896Hoffmann-La Roche153